Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aom-0304
- Development stage
- Phase 2
- Lead developer
- Aomo Pharma
- Modality
- Small Molecules
01
Overview
Aom-0304 is a small molecule drug under preclinical development by Hangzhou Adamerck Pharmlabs. Its primary therapeutic area is cardiovascular diseases, with a specific focus on hypertrophic cardiomyopathy. The precise mechanism of action and molecular targets have not been publicly disclosed as of the latest available update. The drug has not yet entered clinical trials or received regulatory approval.
Beyond the preview
Go deeper on Aom-0304.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aom-0304.